Who We Are

Appili Therapeutics, Inc., was founded in 2015 by a team of drug development, infectious disease and commercialization experts to advance the global fight against infectious disease and the mounting threat of drug-resistant pathogens. Appili’s approach focuses on matching clearly defined medical needs with opportunities for more effective solutions that range from improvements in established therapies to entirely new classes of anti-infectives.

Appili searches for development targets with the philosophy that maintaining or advancing effective therapy for infectious diseases depends on multiple factors. Patient needs arise from both gaps in the current treatment landscape, as well as the impact of tolerability on patient compliance with prescribed medications, access to care, unique disease threats, and other factors that drug developers may overlook or avoid. Incorporating such considerations into assessments of market opportunity allows Appili to choose from a wider range of prospective development assets and pursue a variety of approaches to value generation.

Because of its approach to identifying development opportunities, Appili has been successful in securing a variety of non-dilutive funding sources through partnerships and incentive programs. As a result, the company has a very balanced and clean capital structure.

Appili is planning to submit its first New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in 2018, through the 505(b)(2) pathway, for ATI-1501 in the treatment of parasitic and anaerobic bacterial infections, including Clostridium difficile.

Our Work

This balance of near-to-patient opportunities with higher-risk but potentially transformational programs is reflected in Appili’s growing pipeline:

ATI-1501

A proprietary, taste-masked, oral-suspension technology paired with metronidazole required for the growing number of pediatric and elderly patients with difficulty swallowing

ATI-1503

A drug discovery program for generating candidates in an entirely new class of antibiotic, negamycin analogues, with broad activity against Gram-negative bacteria